skip to main content

Postmenopausal osteoporosis — SCE Endocrinology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCalcium/BonePostmenopausal osteoporosisSCE Endocrinology

A 74-year-old woman with eGFR 42 ml/min/1.73 m2 sustains a fragility hip fracture. DXA later shows femoral neck T-score -2.9 and corrected calcium is normal. She has oesophagitis and cannot tolerate oral bisphosphonates. What is the most appropriate management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: BOffer intravenous zoledronic acid after dental and renal assessment

Offer intravenous zoledronic acid after dental and renal assessment is best because fragility hip fracture with osteoporosis warrants antiresorptive therapy, and intravenous zoledronic acid is suitable when oral bisphosphonates are not tolerated if renal and dental risk permit. The alternatives are less appropriate because avoiding therapy misses secondary prevention; vitamin D alone is insufficient; calcitonin is not preferred long-term treatment; raloxifene is not preferred after hip fracture. The SCE teaching point is to integrate the clinical pattern, biochemistry and context rather than treating an isolated result.

Reference: NICE TA464; NOGG osteoporosis guideline